591 related articles for article (PubMed ID: 25503135)
21. Synergism from combination of cisplatin and a trans-platinum compound in ovarian cancer cell lines.
Alshehri A; Beale P; Yu JQ; Huq F
Anticancer Res; 2010 Nov; 30(11):4547-53. PubMed ID: 21115904
[TBL] [Abstract][Full Text] [Related]
22. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
23. Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells.
Mazumder ME; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Nov; 32(11):4851-60. PubMed ID: 23155251
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, activity and binding with DNA of [{trans-PtCl(NH(3))(2)}(2)micro-{trans-Pd(4-hydroxypyridine) (2) (H(2)N(CH(2))(6)NH(2))(2)]Cl(4) (TH8).
Huq F; Tayyem H; Yu JQ; Beale P; Fisher K
Med Chem; 2009 Jul; 5(4):372-81. PubMed ID: 19689395
[TBL] [Abstract][Full Text] [Related]
25. Enhanced Accumulation of Cisplatin in Ovarian Cancer Cells from Combination with Wedelolactone and Resulting Inhibition of Multiple Epigenetic Drivers.
Sarwar S; Alamro AA; Alghamdi AA; Naeem K; Ullah S; Arif M; Yu JQ; Huq F
Drug Des Devel Ther; 2021; 15():2211-2227. PubMed ID: 34079223
[TBL] [Abstract][Full Text] [Related]
26. Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models.
Althurwi SI; Yu JQ; Beale P; Huq F
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053689
[TBL] [Abstract][Full Text] [Related]
27. Anti-proliferative and pro-apoptotic effects from sequenced combinations of andrographolide and cisplatin on ovarian cancer cell lines.
Yunos NM; Mutalip SS; Jauri MH; Yu JQ; Huq F
Anticancer Res; 2013 Oct; 33(10):4365-71. PubMed ID: 24123004
[TBL] [Abstract][Full Text] [Related]
28. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of trans-(4-hydroxypyridine)(ammine)dichloroplatinum(II) and its activity in the human ovarian tumour models.
Deqnah N; Qing Yu J; Beale P; Fisher K; Huq F
Med Chem; 2013 Jun; 9(4):539-44. PubMed ID: 23061563
[TBL] [Abstract][Full Text] [Related]
30. Studies on two new mixed ligand platinum compounds with a trans-geometry.
Al-Shuneigat J; Yu JQ; Beale P; Fisher K; Huq F
Med Chem; 2010 Sep; 6(5):321-8. PubMed ID: 20977416
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
32. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
[TBL] [Abstract][Full Text] [Related]
33. Changes in the in vitro activity of platinum drugs when administered in two aliquots.
Al-Eisawi Z; Beale P; Chan C; Yu JQ; Proschogo N; Molloy M; Huq F
BMC Cancer; 2016 Aug; 16(1):688. PubMed ID: 27566066
[TBL] [Abstract][Full Text] [Related]
34. Studies of interaction of trichloro{eta2-cis-N,N-dimethyl-1-[6-(N',N'-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammonium}platinum(II) chloride with DNA: Effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin.
Gay M; Montaña AM; Moreno V; Prieto MJ; Pérez JM; Alonso C
Bioorg Med Chem; 2006 Mar; 14(5):1565-72. PubMed ID: 16256352
[TBL] [Abstract][Full Text] [Related]
35. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
36. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
37. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
38. Synergism from combination of cisplatin and multicentred platinums coded as DH6Cl and TH1 in the human ovarian tumour models.
Alshehri A; Beale P; Yu JQ; Huq F
Med Chem; 2011 Nov; 7(6):593-8. PubMed ID: 22313299
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and cytotoxicity of three trans-palladium complexes containing planaramine ligands in human ovarian tumor models.
Mazumder ME; Beale P; Chan C; Yu JQ; Huq F
ChemMedChem; 2012 Oct; 7(10):1840-6. PubMed ID: 22899663
[TBL] [Abstract][Full Text] [Related]
40. Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2011 Nov; 31(11):3789-97. PubMed ID: 22110201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
